Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Taylor

Showing results (731-740 of 750) with videos related to

Pageof 75
Sort By:
Parkinsonism & Related Disorders|January 11, 2025
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline dataTania Nikolcheva, Gennaro Pagano, Nathalie Pross, et al.
NPJ Digital Medicine|June 16, 2025
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumabKirsten I Taylor, Florian Lipsmeier, Marzia A Scelsi, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 28, 2018
Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trialFlorian Lipsmeier, Kirsten I Taylor, Timothy Kilchenmann, et al.
Autism Research : Official Journal of the International Society for Autism Research|September 24, 2017
Adaptive behavior in autism: Minimal clinically important differences on the Vineland-IIC H Chatham, K I Taylor, T Charman, et al.
Nature|December 11, 2024
Structure and mechanism of the Zorya anti-phage defence systemHaidai Hu, Philipp F Popp, Thomas C D Hughes, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 24, 2020
Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and ParkinsonismAhmed Al-Qassabi, Tsu-Shuen Tsao, Adriana Racolta, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 4, 2021
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's DiseaseThomas Kremer, Kirsten I Taylor, Juliane Siebourg-Polster, et al.
European Urology Focus|February 8, 2025
Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non-muscle-invasive Bladder Cancer Undergoing Bladder-sparing TherapiesDrupad Annapureddy, Jacob I Taylor, Ashish M Kamat, et al.
BJU International|August 26, 2024
Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancerJacob I Taylor, Ashish M Kamat, Michael A O'Donnell, et al.
Frontiers in Neurology|October 18, 2021
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline DataGennaro Pagano, Frank G Boess, Kirsten I Taylor, et al.
Pageof 75

Showing results (731-740 of 750) with videos related to

Sort By:
Pageof 75
Parkinsonism & Related Disorders|January 11, 2025
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline dataTania Nikolcheva, Gennaro Pagano, Nathalie Pross, et al.
NPJ Digital Medicine|June 16, 2025
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumabKirsten I Taylor, Florian Lipsmeier, Marzia A Scelsi, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 28, 2018
Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trialFlorian Lipsmeier, Kirsten I Taylor, Timothy Kilchenmann, et al.
Autism Research : Official Journal of the International Society for Autism Research|September 24, 2017
Adaptive behavior in autism: Minimal clinically important differences on the Vineland-IIC H Chatham, K I Taylor, T Charman, et al.
Nature|December 11, 2024
Structure and mechanism of the Zorya anti-phage defence systemHaidai Hu, Philipp F Popp, Thomas C D Hughes, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 24, 2020
Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and ParkinsonismAhmed Al-Qassabi, Tsu-Shuen Tsao, Adriana Racolta, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 4, 2021
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's DiseaseThomas Kremer, Kirsten I Taylor, Juliane Siebourg-Polster, et al.
European Urology Focus|February 8, 2025
Impact of Tumor Stage on Oncologic Outcomes of High-grade Bacillus Calmette-Guérin Unresponsive Non-muscle-invasive Bladder Cancer Undergoing Bladder-sparing TherapiesDrupad Annapureddy, Jacob I Taylor, Ashish M Kamat, et al.
BJU International|August 26, 2024
Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancerJacob I Taylor, Ashish M Kamat, Michael A O'Donnell, et al.
Frontiers in Neurology|October 18, 2021
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline DataGennaro Pagano, Frank G Boess, Kirsten I Taylor, et al.
Pageof 75